This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Takeda.
tumour necrosis factor
Reference
Wilson MR, et al. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. ClinicoEconomics and Outcomes Research : 16 Oct 2017. Available from: URL: https://doi.org/10.2147/CEOR.S135609
Rights and permissions
About this article
Cite this article
Vedolizumab a cost-effective option in UC in the UK. PharmacoEcon Outcomes News 790, 34 (2017). https://doi.org/10.1007/s40274-017-4479-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4479-5